CN100337665C - 治疗糖尿病的口服药物 - Google Patents
治疗糖尿病的口服药物 Download PDFInfo
- Publication number
- CN100337665C CN100337665C CNB2005100416107A CN200510041610A CN100337665C CN 100337665 C CN100337665 C CN 100337665C CN B2005100416107 A CNB2005100416107 A CN B2005100416107A CN 200510041610 A CN200510041610 A CN 200510041610A CN 100337665 C CN100337665 C CN 100337665C
- Authority
- CN
- China
- Prior art keywords
- radix
- parts
- portions
- present
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 112
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 claims abstract description 34
- 239000002994 raw material Substances 0.000 claims abstract description 27
- 239000009636 Huang Qi Substances 0.000 claims description 24
- 239000008517 radix Trichosanthis Substances 0.000 claims description 22
- 241000605447 Anemarrhena Species 0.000 claims description 9
- 235000005903 Dioscorea Nutrition 0.000 claims description 9
- 241000234273 Dioscorea Species 0.000 claims description 9
- 235000000504 Dioscorea villosa Nutrition 0.000 claims description 9
- 241001523579 Ostrea Species 0.000 claims description 9
- 235000004879 dioscorea Nutrition 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 229940126701 oral medication Drugs 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 abstract description 100
- 239000008280 blood Substances 0.000 abstract description 100
- 235000000346 sugar Nutrition 0.000 abstract description 64
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 57
- 239000008103 glucose Substances 0.000 abstract description 57
- 241000700159 Rattus Species 0.000 abstract description 35
- 238000012360 testing method Methods 0.000 abstract description 34
- 201000001421 hyperglycemia Diseases 0.000 abstract description 31
- 230000006870 function Effects 0.000 abstract description 16
- 241000283973 Oryctolagus cuniculus Species 0.000 abstract description 15
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 abstract description 7
- 229930182837 (R)-adrenaline Natural products 0.000 abstract description 7
- 229960005139 epinephrine Drugs 0.000 abstract description 7
- 230000003285 pharmacodynamic effect Effects 0.000 abstract description 2
- 241000605445 Anemarrhena asphodeloides Species 0.000 abstract 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 abstract 1
- 235000002722 Dioscorea batatas Nutrition 0.000 abstract 1
- 235000006536 Dioscorea esculenta Nutrition 0.000 abstract 1
- 240000001811 Dioscorea oppositifolia Species 0.000 abstract 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 abstract 1
- 229930195210 Ophiopogon Natural products 0.000 abstract 1
- 244000248557 Ophiopogon japonicus Species 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 244000081426 Ranunculus ficaria Species 0.000 abstract 1
- 235000002226 Ranunculus ficaria Nutrition 0.000 abstract 1
- 235000008326 Trichosanthes anguina Nutrition 0.000 abstract 1
- 244000078912 Trichosanthes cucumerina Species 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 239000007928 intraperitoneal injection Substances 0.000 abstract 1
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 44
- 230000000694 effects Effects 0.000 description 33
- 238000005516 engineering process Methods 0.000 description 25
- 229940079593 drug Drugs 0.000 description 23
- 241001465754 Metazoa Species 0.000 description 20
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- 238000005242 forging Methods 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 16
- 239000002775 capsule Substances 0.000 description 15
- 230000003203 everyday effect Effects 0.000 description 15
- 235000001727 glucose Nutrition 0.000 description 15
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 14
- 150000004676 glycans Chemical class 0.000 description 13
- 230000002218 hypoglycaemic effect Effects 0.000 description 13
- 229920001282 polysaccharide Polymers 0.000 description 13
- 239000005017 polysaccharide Substances 0.000 description 13
- 239000011780 sodium chloride Substances 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 239000003826 tablet Substances 0.000 description 12
- 239000002671 adjuvant Substances 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 239000000284 extract Substances 0.000 description 10
- 230000002496 gastric effect Effects 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 210000002784 stomach Anatomy 0.000 description 10
- 239000008187 granular material Substances 0.000 description 9
- 238000001802 infusion Methods 0.000 description 9
- 102000004877 Insulin Human genes 0.000 description 8
- 108090001061 Insulin Proteins 0.000 description 8
- 238000010241 blood sampling Methods 0.000 description 8
- 229940125396 insulin Drugs 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 229920002472 Starch Polymers 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 238000010998 test method Methods 0.000 description 6
- 208000013016 Hypoglycemia Diseases 0.000 description 5
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical group C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 5
- 210000004100 adrenal gland Anatomy 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 229940090044 injection Drugs 0.000 description 5
- 238000010253 intravenous injection Methods 0.000 description 5
- 238000003032 molecular docking Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 230000001550 time effect Effects 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 229940123208 Biguanide Drugs 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 208000007241 Experimental Diabetes Mellitus Diseases 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 208000003455 anaphylaxis Diseases 0.000 description 3
- 150000004283 biguanides Chemical class 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 150000002338 glycosides Chemical class 0.000 description 3
- 229940095686 granule product Drugs 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 241001061264 Astragalus Species 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 239000004366 Glucose oxidase Substances 0.000 description 2
- 108010015776 Glucose oxidase Proteins 0.000 description 2
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000001466 anti-adreneric effect Effects 0.000 description 2
- 235000006533 astragalus Nutrition 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000002481 ethanol extraction Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 229960004580 glibenclamide Drugs 0.000 description 2
- 229940116332 glucose oxidase Drugs 0.000 description 2
- 235000019420 glucose oxidase Nutrition 0.000 description 2
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000000575 pesticide Substances 0.000 description 2
- 229960003243 phenformin Drugs 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 206010036067 polydipsia Diseases 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 229930002600 steroidal saponin Natural products 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000004233 talus Anatomy 0.000 description 2
- 229930182493 triterpene saponin Natural products 0.000 description 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000009022 Jinqi Substances 0.000 description 1
- 206010023379 Ketoacidosis Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 206010068676 Pneumoretroperitoneum Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000005727 Retropneumoperitoneum Diseases 0.000 description 1
- 241000594182 Sarcophaga sigma Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000025371 Taste disease Diseases 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 235000009392 Vitis Nutrition 0.000 description 1
- 241000219095 Vitis Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- LAISNASYKAIAIK-UHFFFAOYSA-N [S].[As] Chemical compound [S].[As] LAISNASYKAIAIK-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229960001761 chlorpropamide Drugs 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229960000346 gliclazide Drugs 0.000 description 1
- 229940093181 glucose injection Drugs 0.000 description 1
- 150000002304 glucoses Chemical class 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 235000019656 metallic taste Nutrition 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 206010040400 serum sickness Diseases 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
组别 | 动物数(只) | 剂量g/kg | 血糖水平(mmol/L) | 差值(mmol/L) | ||
造模前 | 造模给药前 | 造模给药后 | ||||
正常盐水对照组 | 10 | 3.39±0.38 | 4.21±2.02 | 3.83±1.58 | -0.38±0.646 | |
高糖模型盐水组 | 10 | 3.30±1.00 | 8.59±3.10△△ | 8.41±3.04 | -0.175±2.07 | |
模型+降糖灵 | 10 | 0.09 | 3.37±1.46 | 8.47±2.60△△ | 3.15±1.08** | -5.31±2.01** |
模型+本发明大剂量 | 10 | 2.5 | 3.59±1.40 | 8.12±2.41△△ | 2.95±1.05** | -5.13±1.84** |
模型+本发明中剂量 | 10 | 0.8 | 3.83±1.31 | 7.41±3.17△△ | 4.23±1.63** | -3.18±1.72** |
模型+本发明小剂量 | 10 | 0.27 | 4.06±1.64 | 8.88±5.11△ | 7.48±6.08 | -1.92±1.87 |
组别 | 剂量(g/kg) | 给药前血糖(mmol/L) | 给药后血糖(mmol/L) | ||
30分钟 | 60分钟 | 90分钟 | |||
正常对照组 | 3.56±1.10 | 4.14±2.09 | 5.42±1.61 | 4.40±1.74 | |
模型组 | 3.97±1.61 | 9.52±4.70△△ | 7.84±1.74△△ | 4.97±0.73 | |
模型+降糖灵 | 0.09 | 3.76±1.30 | 6.97±2.26 | 4.67±1.39** | 3.93±1.76 |
模型+本发明大剂量 | 2.80 | 3.55±0.98 | 5.55±2.39* | 3.07±1.92** | 3.60±1.87* |
模型+本发明中剂量 | 0.93 | 3.37±1.61 | 8.00±2.34 | 4.21±2.15** | 5.09±1.87 |
模型+本发明小剂量 | 0.31 | 3.08±0.71 | 9.60±2.11 | 5.04±1.72** | 4.68±1.95 |
组别 | 动物数(只) | 剂量(g/kg) | 给药前血糖(mmol/L) | 末次给药后不同时间血糖水平(mmol/L) | |
0.5小时 | 1.0小时 | ||||
盐水对照组 | 10 | 6.28±2.13 | 6.39±2.27 | 6.55±1.85 | |
降糖灵 | 10 | 0.09 | 6.44±2.83 | 3.70±1.85△** | 3.75±0.95**△ |
本发明大计量 | 10 | 2.88 | 6.45±1.69 | 4.86±1.74 | 5.54±1.80*△ |
本发明中计量 | 10 | 0.93 | 6.87±2.70 | 5.23±2.01 | 4.23±1.53**△ |
本发明小计量 | 10 | 0.31 | 6.39±1.22 | 6.13±1.27 | 5.81±1.43 |
组别(+葡萄糖) | 动物数 | 剂量g/kg | 给药前(mmol/L) | Ip葡萄糖(mmol/L) | 血糖曲线下面积mmol/Lh | |||
0.5小时 | 1小时 | 2小时 | 3小时 | |||||
盐水 | 6 | 4.82±0.55 | 13.82±4.67 | 14.02±3.48 | 4.76±1.69 | 5.43±2.16 | 21.45±4.52 | |
降糖灵 | 6 | 0.06 | 4.32±0.70 | 8.15±3.83* | 6.69±1.90** | 4.35±1.52 | 4.76±1.58 | 13.78±3.92** |
本发明大剂量 | 6 | 2.5 | 4.82±1.23 | 6.02±0.32** | 4.32±0.96** | 2.66±0.58** | 3.42±2.79 | 9.11±1.39** |
本发明中剂量 | 6 | 0.8 | 4.35±0.25 | 8.00±0.91* | 5.20±1.99** | 3.21±1.84 | 3.76±1.52 | 9.83±1.99** |
本发明小剂量 | 6 | 0.27 | 3.91±1.08 | 13.09±6.66 | 12.15±8.41 | 3.33±1.20 | 4.21±0.79 | 17.64±6.50 |
组别 | 动物数(n) | 剂量(g/kg) | 造模前血糖值(mmol/L) | 给药前血糖值(mmol/L) | 模型血糖值(mmol/L) | ||||
给药后及血糖下降% | |||||||||
0.5 | 1 | 2 | 3 | 4(h) | |||||
模型盐水对照组 | 16 | 10ml/kg | 2.68±0.56 | 19.22±3.70 | 19.31±3.790.7% | 19.36±3.780.5% | 19.31±3.750.4% | 19.29±3.160.4% | 19.30±3.680.4% |
降糖灵对照组 | 15^ | 0.08 | 2.65±0.43 | 19.17±4.82 | 17.13±3.9410.6% | 14.08±3.30**26.6% | 16.31±3.93*14.9% | 17.50±4.118.7% | 17.72±4.057.7% |
本发明大剂量 | 16 | 2.5 | 2.66±0.34 | 19.74±3.34 | 18.29±2.967.3% | 15.49±0.99**21.5% | 17.38±2.9811.9% | 15.55±1.671.0% | 19.53±1.591.1% |
本发明中剂量 | 14^ | 1.0 | 2.66±0.32 | 19.32±3.12 | 18.01±2.795.6% | 18.16±2.856.0% | 18.24±2.905.6% | 18.28±2.935.4% | 18.34±2.975.1% |
本发明小剂量 | 16 | 0.5 | 2.67±0.31 | 18.95±2.57 | 17.41±2.608.2% | 17.85±2.495.8% | 17.9±2.675.5% | 17.84±2.595.9% | 18.24±2.933.7% |
组别 | 大鼠数(n) | 剂量(g/kg) | 造模前血糖值(mol/L) | 造模后血糖值(mol/L) | 给药后血糖(mol/L及)及下降值(%) | 停药后血糖(mol/L)及下降值(%) | ||||||||
1 | 3 | 5 | 7 | 9 | 11 | 13(d) | 1 | 2 | 3(d) | |||||
模型盐水对照组 | 18 | 10ml/kg | 2.78±0.45 | 17.94±1.98 | 18.18±2.02-1.3% | 18.20±1.95-1.5% | 18.19±1.89-1.4% | 18.10±1.86-0.9% | 18.04±1.82-0.6% | 18.13±1.86-1.1% | 17.91±1.810.2% | 17.80±1.82-0.3% | 18.08±2.06-0.8% | 18.21±2.14-1.5% |
降糖灵 | 17^ | 0.08 | 2.78±0.43 | 18.15±2.46 | 14.62±2.13**19.5% | 13.08±1.80**27.9% | 11.70±1.96**35.5% | 10.44±1.96**42.5% | 9.18±1.81**49.4% | 8.34±2.03**54.1% | 7.83±1.98**56.9% | 8.26±2.03**54.5% | 8.23±2.02**54.7% | 8.25±2.00**54.5% |
本发明大剂量 | 18 | 2.5 | 2.70±1.41 | 18.10±2.81 | 15.21±2.65**16.0% | 13.91±2.40*23.2% | 12.72±2.40**29.8% | 11.51±2.10**36.4% | 11.61±2.12*35.9% | 11.71±2.11**35.3% | 11.81±2.00**34.8% | 11.81±2.10**34.8% | 11.91±2.01**34.2% | 11.91±2.10**34.2% |
本发明中剂量 | 18 | 1.0 | 2.67±0.42 | 18.36±2.61 | 17.97±2.532.1% | 17.78±2.473.2% | 17.63±2.353.9% | 17.67±2.383.7% | 17.71±2.493.6% | 17.67±2.454.1% | 17.71±2.463.6% | 17.51±2.524.7% | 17.61±2.524.1% | 17.60±2.564.1% |
本发明小剂量 | 16^ | 0.5 | 2.73±0.42 | 18.41±2.45 | 17.82±2.423.2% | 17.61±2.334.3% | 17.41±2.135.4% | 17.61±2.104.4% | 17.61±2.114.4% | 17.67±2.143.8% | 17.67±2.103.9% | 17.55±2.124.6% | 17.61±2.134.4% | 17.70±2.123.9% |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100416107A CN100337665C (zh) | 2005-01-07 | 2005-01-07 | 治疗糖尿病的口服药物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100416107A CN100337665C (zh) | 2005-01-07 | 2005-01-07 | 治疗糖尿病的口服药物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1679820A CN1679820A (zh) | 2005-10-12 |
CN100337665C true CN100337665C (zh) | 2007-09-19 |
Family
ID=35066826
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100416107A Expired - Fee Related CN100337665C (zh) | 2005-01-07 | 2005-01-07 | 治疗糖尿病的口服药物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100337665C (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102266472B (zh) * | 2011-07-29 | 2013-08-07 | 仝小林 | 预防和/或治疗糖尿病肾病的中药组合物及其制备方法 |
CN102755568B (zh) * | 2012-07-27 | 2014-06-25 | 贵州文旺薏苡仁开发有限责任公司 | 辅助降血糖的保健品及其制备方法 |
CN103948786B (zh) * | 2014-04-01 | 2015-02-04 | 张默 | 一种治疗糖尿病的中药 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1108109A (zh) * | 1994-03-08 | 1995-09-13 | 哈尔滨中药三厂 | 糖尿病治疗剂的配方 |
CN1304751A (zh) * | 2000-12-01 | 2001-07-25 | 张志祥 | 玄参胶囊及其制备方法 |
-
2005
- 2005-01-07 CN CNB2005100416107A patent/CN100337665C/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1108109A (zh) * | 1994-03-08 | 1995-09-13 | 哈尔滨中药三厂 | 糖尿病治疗剂的配方 |
CN1304751A (zh) * | 2000-12-01 | 2001-07-25 | 张志祥 | 玄参胶囊及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1679820A (zh) | 2005-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1298363C (zh) | 一种辅助降血糖的保健食品及其制备方法 | |
CN1947757A (zh) | 地黄叶提取物及其制备方法和用途、用该提取物制备的药物 | |
CN1075735C (zh) | 治疗糖尿病的中药复方制剂及其制备方法 | |
CN1857654A (zh) | 气管炎制剂及新的制备方法 | |
CN100337665C (zh) | 治疗糖尿病的口服药物 | |
CN1239183C (zh) | 一种中药组合物及其制备方法 | |
CN1813819A (zh) | 猴头子实体或猴头菌丝体及培养物提取物及制剂和制法 | |
CN1246011C (zh) | 藕节提取物在制备改善人体胰岛素抵抗和治疗或预防肥胖症的药物中的应用 | |
CN100344315C (zh) | 一种促进骨折愈合的药物组合物及其制备方法 | |
CN1562337A (zh) | 治疗肾阳虚的中药及其制备方法 | |
CN1212141C (zh) | 苍术油在制备治疗骨质疏松症药物中的应用 | |
CN1733089A (zh) | 治疗糖尿病及并发症的药物及其制备方法 | |
CN1634463A (zh) | 治疗糖尿病的药物及生产方法 | |
CN1283300C (zh) | 一种治疗糖尿病的中药组合物及其制备方法 | |
CN1686485A (zh) | 一种治疗冠心病心绞痛的药物组合物及其制备方法 | |
CN1569195A (zh) | 一种圣地红景天软胶囊制剂及其制备方法 | |
CN1211111C (zh) | 一种降血脂中药 | |
CN1742936A (zh) | 一种治疗糖尿病的天然药物制剂及其制备方法 | |
CN1666658A (zh) | 一种适用于糖尿病病人的保健品及其生产方法 | |
CN1287834C (zh) | 一种治疗冠心病、心绞痛的颗粒剂及其制备方法 | |
CN101062314A (zh) | 一种治疗痛风的药物及其制备方法 | |
CN1602945A (zh) | 通窍鼻炎软胶囊及其制备工艺 | |
CN1562144A (zh) | 治疗肠易激综合症的中药组合物及其制备方法 | |
CN1682934A (zh) | 玉泉浸膏及其药物组合物和用途 | |
CN1785348A (zh) | 治疗ⅱ型糖尿病、降低血糖的中药复方制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: SHANXI BOSEN BIOLOGY PHARMACY STOCK GROUP CO., LTD Free format text: FORMER NAME OR ADDRESS: SHAANXI BERSON BIOLOGICAL PHARMACEUTICAL CO., LTD. |
|
CP03 | Change of name, title or address |
Address after: No. 7, innovation road, new industrial park, hi tech Industrial Development Zone, Shaanxi, Xi'an Patentee after: Shaanxi Bosen Biological Pharmaceutical Group Co., Ltd. Address before: No. 7, Chuangxin Road, Changan science and Technology Industrial Park, Shaanxi, Xi'an Patentee before: Bosen Bio-Pharmaceutical Co., Ltd., Shanxi Province |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Oral medicine for curing diabetes and its producing method Effective date of registration: 20150629 Granted publication date: 20070919 Pledgee: Shaanxi credit re Company Limited by Guarantee Pledgor: Shaanxi Bosen Biological Pharmaceutical Group Co., Ltd. Registration number: 2015980000126 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20160727 Granted publication date: 20070919 Pledgee: Shaanxi credit re Company Limited by Guarantee Pledgor: Shaanxi Bosen Biological Pharmaceutical Group Co., Ltd. Registration number: 2015980000126 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Oral medicine for curing diabetes and its producing method Effective date of registration: 20161205 Granted publication date: 20070919 Pledgee: Shaanxi credit re Company Limited by Guarantee Pledgor: Shaanxi Bosen Biological Pharmaceutical Group Co., Ltd. Registration number: 2016980000183 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20180713 Granted publication date: 20070919 Pledgee: Shaanxi credit re Company Limited by Guarantee Pledgor: Shaanxi Bosen Biological Pharmaceutical Group Co., Ltd. Registration number: 2016980000183 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070919 Termination date: 20210107 |
|
CF01 | Termination of patent right due to non-payment of annual fee |